Immunotherapy in head and neck squamous cell carcinoma: An updated review.

By K. Parmar, A. Mohamed, E. Vaish, R. Thawani, J. Cetnar, KZ Thein. 2022

Subfields: Immunology, Oncology

Citations in the corpus

• Special Issue “Pathogenesis and Treatments of Head and Neck Cancer” (2025, unknown): “Immunotherapy, particularly PD-1/PD-L1 inhibitors such as pembrolizumab and nivolumab, has become the standard of care for recurrent and metastatic disease, providing durable responses in a subset of patients [20].”